FDA grants breakthrough device designations to Avita's Recell device for soft tissue repair, vitiligo - BioWorld Online

• BioWorld
• BioWorld MedTech
• BioWorld Asia
• BioWorld Science
• Data Snapshots
  • BioWorld
  • BioWorld MedTech
• Special reports
  • Aging
  • Biosimilars
  • Artificial intelligence
  • Coronavirus
  • IVDs connected the rise
  • Top Biopharma Trends of 2021
  • Top Med-tech Trends of 2021
  • Premium reports
    • BioWorld Financings Reports
    • Disease Incidence & Prevalence Summaries

• Sign In
• Sign Out
• My Account

Subscribe

X

Subscribe to BioWorld™ quality services

See subscription options

Avita Medical Ltd.’s Recell strategy won FDA breakthrough instrumentality designations successful brushed insubstantial repair and vitiligo. Melbourne-headquartered Avita, a regenerative medicine institution developed the Recell system, a exertion level that enables point-of-care autologous tegument restoration.

BioWorld MedTech Regulatory Asia-Pacific Australia